In Romania, reimbursed standard treatment for HR-positive HER2-negative advanced breast cancer tumors is aligned with European Guidelines [13], which recommends a preferred first-line as CDK4/6 inhibitor plus ET. Here, ERBB2 is linked to breast carcinoma.